The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Open accessAbstract
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase belonging to the HER family of receptor tyrosine kinases. Receptor activation upon ligand binding leads to down stream activation of the PI3K/AKT, RAS/RAF/MEK/ERK and PLCγ/PKC pathways that influence cell proliferation, survival and the metastatic potential of tumor cells. Increased activation by gene amplification, protein overexpression or mutations of the EGFR has been identified as an etiological factor in a number of human epithelial cancers (e.g., NSCLC, CRC, glioblastoma and breast cancer). Therefore, targeting the EGFR has been intensely pursued as a cancer treatment strategy over the last two decades. To date, five EGFR inhibitors, including three small molecule tyrosine kinase inhibitors (TKIs) and two monoclonal antibodies have gained FDA approval for use in oncology. Both approaches to targeting the EGFR have shown clinical promise and the anti-EGFR antibody cetuximab is used to treat HNSCC and CRC. Despite clinical gains arising from use of cetuximab, both intrinsic resistance and the development of acquired resistance are now well recognized. In this review we focus on the biology of the EGFR, the role of EGFR in human cancer, the development of antibody-based anti-EGFR therapies and a summary of their clinical successes. Further, we provide an in depth discussion of described molecular mechanisms of resistance to cetuximab and potential strategies to circumvent this resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Transforming gene product of Rous sarcoma virus phosphorylates tyrosine
Hunter, T., & Sefton, B. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1311 · Cited by 2,332
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Molecular requirements for epithelial–mesenchymal transition during tumor progression
Huber, M. A., Kraut, N., & Beug, H. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.08.001 · Cited by 1,821
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
Pirker, R., Pereira, J. R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., Vynnychenko, I., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,351
A Cytoplasmic Protein Stimulates Normal N- ras p21 GTPase, But Does Not Affect Oncogenic Mutants
Trahey, M., & McCormick, F. (1987) · Science · doi:10.1126/science.2821624 · Cited by 1,211
Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
Targeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
Nuclear localization of EGF receptor and its potential new role as a transcription factor
Lin, S.-Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-802 · Cited by 1,064
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Protein kinase C and other diacylglycerol effectors in cancer
Griner, E. M., & Kazanietz, M. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2110 · Cited by 978
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 946
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Control of EGF receptor signaling by clathrin-mediated endocytosis
Vieira, A. V., Lamaze, C., & Schmid, S. L. (1996) · Science · doi:10.1126/science.274.5295.2086 · Cited by 883
Burtness, B., Goldwasser, M. A., Flood, W., Mattar, B., & Forastiere, A. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4646 · Cited by 879
Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., & Mendelsohn, J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1337 · Cited by 791
Goldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 785
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00848.x · Cited by 740
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation
Haglund, K., Sigismund, S., Polo, S., Szymkiewicz, I., Di Fiore, P. P., & Dikic, I. (2003) · Nature Cell Biology · doi:10.1038/ncb983 · Cited by 715
Huang, S., Bock, J. M., & Harari, P. M. (1999) · PubMed · Cited by 714
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698
Carcinoma Invasion and Metastasis: A Role for Epithelial-Mesenchymal Transition?
Thompson, E. W., & Newgreen, D. F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0616 · Cited by 667
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., & Dinney, C. P. (1999) · PubMed · Cited by 647
Pratilas, C. A., Taylor, B. S., Ye, Q., Viale, A., Sander, C., Solit, D. B., & Rosen, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900780106 · Cited by 614
Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.
Marais, R., Light, Y., Paterson, H. F., & Marshall, C. J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07316.x · Cited by 612
Cbl–CIN85–endophilin complex mediates ligand-induced downregulation of EGF receptors
Soubeyran, P., Kowanetz, K., Szymkiewicz, I., Langdon, W. Y., & Dikic, I. (2002) · Nature · doi:10.1038/416183a · Cited by 582
The EGFR as a target for anticancer therapy—focus on cetuximab
Baselga, J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00233-7 · Cited by 563
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
Wheeler, D. L., Huang, S., Kruser, T. J., Nechrebecki, M. M., Armstrong, E. A., Benavente, S., Gondi, V, Hsu, K.-T., & Harari, P. M. (2008) · Oncogene · doi:10.1038/onc.2008.19 · Cited by 550
Self-citationNuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
Lo, H.-W., Hsu, S.-C., Ali-Seyed, M., Gunduz, M., Xia, W., Wei, Y., Bartholomeusz, G., Shih, J.-Y., & Hung, M.-C. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.007 · Cited by 544
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
Frattini, M., Saletti, P., Romagnani, E., Martin, V, Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L. L., Cavalli, F., & Mazzucchelli, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604009 · Cited by 540
An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates
Eckhart, W., Hutchinson, M. A., & Hunter, T. (1979) · Cell · doi:10.1016/0092-8674(79)90205-8 · Cited by 525
Baselga, J., Trigo, J. M., Bourhis, J., Tortochaux, J., Cortés-Funes, H., Hitt, R., Gascón, P., Amellal, N., Harstrick, A., & Eckardt, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.119 · Cited by 490
Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3234 · Cited by 474
Expression of epidermal growth factor receptors in human brain tumors.
Libermann, T. A., Razon, N., Bartal, A. D., Yarden, Y., Schlessinger, J., & Soreq, H. (1984) · PubMed · Cited by 473
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Yang, X. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00134-7 · Cited by 463
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.
Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J. M., Polikoff, J., & SATO, G. H. (1983) · PubMed · Cited by 458
Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., & Yarden, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4995 · Cited by 455
Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., & Mendelsohn, J. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42857-2 · Cited by 455
Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro
CARPENTER, G., KING, L., & COHEN, S. (1978) · Nature · doi:10.1038/276409a0 · Cited by 454
All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired
Baulida, J., Kraus, M. H., Alimandi, M., Fiore, P. P. D., & Carpenter, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.5251 · Cited by 454
Lynch, T. J., Patel, T., Dreisbach, L., McCleod, M., Heim, W. J., Hermann, R. C., Paschold, E., Iannotti, N. O., Dakhil, S., Gorton, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9618 · Cited by 447
Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., & Mendelsohn, J. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)50005-1 · Cited by 446
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436
Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts
Carpenter, G., Lembach, K., Morrison, M., & Cohen, S. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)41417-8 · Cited by 435
Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435
Bruns, C. J., Harbison, M. T., Davis, D. W., Portera, C. A., Tsan, R. Z., McConkey, D. J., Evans, D. B., Abbruzzese, J. L., Hicklin, D. J., & Radinsky, R. (2000) · PubMed · Cited by 422
The role of vascular endothelial growth factor in pathological angiogenesis
Ferrara, N. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666035 · Cited by 414
Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., & Ullrich, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00101.x · Cited by 406
Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., Masi, G., Graziano, F., Cremolini, C., Rulli, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2796 · Cited by 403
Herbst, R. S., Arquette, M., Shin, D. M., Dicke, K., Vokes, E. E., Azarnia, N., Hong, W. K., & Kies, M. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.120 · Cited by 402
Autocrine, paracrine and juxtacrine signaling by EGFR ligands
Singh, A. B., & Harris, R. C. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.03.026 · Cited by 400
Signal transduction by allosteric receptor oligomerization
Schlessinger, J. (1988) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(88)90219-8 · Cited by 399
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases
Marmor, M. D., & Yarden, Y. (2004) · Oncogene · doi:10.1038/sj.onc.1207390 · Cited by 383
Humphrey, P. A., Wong, A. J., Vogelstein, B., Zalutsky, M. R., Fuller, G. N., Archer, G. E., Friedman, H. S., Kwatra, M. M., Bigner, S. H., & Bigner, D. D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4207 · Cited by 382
Wu, X., Fan, Z., Masui, H., Rosen, N., & Mendelsohn, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117871 · Cited by 381
Ciardiello, F., Bianco, R., Damiano, V., Fontanini, G., Caputo, R., Pomatico, G., Placido, S. D., Bianco, A. R., Mendelsohn, J. M., & Tortora, G. (2000) · PubMed · Cited by 378
Targeting the protein kinase C family: are we there yet?
Mackay, H. J., & Twelves, C. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2168 · Cited by 373
Van Cutsem, E., Lang, I., D'haens, G., Moiseyenko, V., Zaluski, J., Folprecht, G., Tejpar, S., Kisker, O., Stroh, C., & Rougier, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2 · Cited by 372
Expression of epidermal growth factor receptor in human gastric and colonic carcinomas.
Yasui, W., Sumiyoshi, H., Hata, J., Kameda, T., Ochiai, A., Ito, H., & Tahara, E. (1988) · PubMed · Cited by 357
Ciardiello, F., Bianco, R., Caputo, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1100-03 · Cited by 347
Sartore-Bianchi, A., Moroni, M., Veronese, S., Carnaghi, C., Bajetta, E., Luppi, G., Sobrero, A., Barone, C., Cascinu, S., Colucci, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5956 · Cited by 333
Epidermal growth factor receptors in non-small cell lung cancer
Veale, D., Ashcroft, T., Marsh, C., Gibson, G., & Harris, A. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.104 · Cited by 327
Worthylake, R., Opresko, L. K., & Wiley, H. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8865 · Cited by 325
Lo, H.-W., & Hung, M.-C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602941 · Cited by 323
Tyrosine phosphorylation controls PCNA function through protein stability
Wang, S.-C., Nakajima, Y., Yu, Y.-L., Xia, W., Chen, C.-T., Yang, C.-C., McIntush, E. W., Li, L.-Y., Hawke, D. H., Kobayashi, R., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1501 · Cited by 322
Regulated Migration of Epidermal Growth Factor Receptor from Caveolae
Mineo, C., Gill, G. N., & Anderson, R. G. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30636 · Cited by 320
Mukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S., Lindeman, N., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 318
Nuclear EGFR contributes to acquired resistance to cetuximab
Li, C., Iida, M., Dunn, E. F., Ghia, A. J., & Wheeler, D. L. (2009) · Oncogene · doi:10.1038/onc.2009.234 · Cited by 313
Self-citationFuchs, B. C., Fujii, T., Dorfman, J. D., Goodwin, J. M., Zhu, A. X., Lanuti, M., & Tanabe, K. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2460 · Cited by 309
Fontanini, G., Vignati, S., Boldrini, L., Chinè, S., Silvestri, V., Lucchi, M., Mussi, A., Angeletti, C. A., & Bevilacqua, G. (1997) · PubMed · Cited by 306
Spitaler, M., & Cantrell, D. A. (2004) · Nature Immunology · doi:10.1038/ni1097 · Cited by 302
Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer
Lo, H.-W., Xia, W., Wei, Y., Ali-Seyed, M., Huang, S.-F., & Hung, M.-C. (2005) · Cancer Research · doi:10.1158/0008-5472.338.65.1 · Cited by 290
Peng, D., Fan, Z., Yang, L., DeBlasio, T., Scher, H. I., & Mendelsohn, J. M. (1996) · PubMed · Cited by 280
Kimura, H., Sakai, K., Arao, T., Shimoyama, T., Tamura, T., & Nishio, K. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00510.x · Cited by 277
Troussard, A. A., Mawji, N. M., Ong, C., Mui, A., St.-Arnaud, R., & Dedhar, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303083200 · Cited by 276
Endocytosis of growth factor receptors
Sorkin, A., & Waters, C. M. (1993) · BioEssays · doi:10.1002/bies.950150603 · Cited by 272
Hirsch, F. R., Herbst, R. S., Olsen, C., Chansky, K., Crowley, J., Kelly, K., Franklin, W. A., Bunn, P. A., Varella-Garcia, M., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0111 · Cited by 271
Psyrri, A., Yu, Z., Weinberger, P. M., Sasaki, C., Haffty, B., Camp, R., Rimm, D., & Burtness, B. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0420 · Cited by 269
Cappuzzo, F., Finocchiaro, G., Rossi, E., Jänne, P. A., Carnaghi, C., Calandri, C., Bencardino, K., Ligorio, C., Ciardiello, F., Pressiani, T., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm492 · Cited by 267
Khambata-Ford, S., Harbison, C. T., Hart, L. L., Awad, M., Xu, L.-A., Horak, C. E., Dakhil, S., Hermann, R. C., Lynch, T. J., & Weber, M. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2890 · Cited by 266
Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family
Hsu, S.-C., & Hung, M.-C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610014200 · Cited by 260
Rosell, R., Robinet, G., Szczesna, A., Ramlau, R., Constenla, M., Mennecier, B. C., Pfeifer, W., O’Byrne, K. J., Welte, T., Kolb, R., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm474 · Cited by 258
Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., SATO, G. H., & Mendelsohn, J. (1984) · PubMed · Cited by 254
Santini, J., Formento, J., Francoual, M., Milano, G., Schneider, M., Dassonville, O., & Demard, F. (1991) · Head & Neck · doi:10.1002/hed.2880130209 · Cited by 254
Sunada, H., Magun, B. E., Mendelsohn, J., & MacLeod, C. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.3825 · Cited by 253
Lo, H.-W., Cao, X., Zhu, H., & Ali-Osman, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4923 · Cited by 253
Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma
Maurizi, M., Almadori, G., Ferrandina, G., Distefano, M., Romanini, M., Cadoni, G., Benedetti-Panici, P., Paludetti, G., Scambia, G., & Mancuso, S. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.525 · Cited by 250
Jung, Y. D., Mansfield, P. F., Akagi, M., Takeda, A., Liu, W., Bucana, C. D., Hicklin, D. J., & Ellis, L. M. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00013-8 · Cited by 249
Phospholipase C-γ as a Signal-Transducing Element
Carpenter, G., & Ji, Q.-S. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4671 · Cited by 246
van der Kevie-Kersemaekers, A.-M. F., Fleuren, G. J., Kenter, G. G., den Broek, L. J. C. M. V., Kolkman-Uljee, S. M., Hermans, J., & van de Vijver, M. J. (1999) · PubMed · Cited by 245
Bokemeyer, C., Bondarenko, I., Hartmann, J. T., De Braud, F. G., Volovat, C., Nippgen, J., Stroh, C., Celik, I., & Koralewski, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4000 · Cited by 240
Nuclear‐cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1
Lo, H., Ali‐Seyed, M., Wu, Y., Bartholomeusz, G., Hsu, S., & Hung, M. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20876 · Cited by 240
Lo, H.-W., Hsu, S.-C., & Hung, M.-C. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9011-0 · Cited by 237
Escape from Cbl-mediated downregulation
Peschard, P., & Park, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00136-3 · Cited by 233
Bandyopadhyay, D., Mandal, M., Adam, L., Mendelsohn, J., & Kumar, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1568 · Cited by 229
Wu, X., Rubin, M., Fan, Z., DeBlasio, T., Soos, T. J., Koff, A., & Mendelsohn, J. M. (1996) · PubMed · Cited by 228
Defective downregulation of receptor tyrosine kinases in cancer
Bache, K. G., Slagsvold, T., & Stenmark, H. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600292 · Cited by 212
Tol, J., Koopman, M., Rodenburg, C. J., Cats, A., Creemers, G. J., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., Mol, L., Antonini, N. F., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm607 · Cited by 212
Thienelt, C. D., Bunn, P. A., Hanna, N., Rosenberg, A., Needle, M. N., Long, M. E., Gustafson, D. L., & Kelly, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1997 · Cited by 203
Dittmann, K., Mayer, C., Kehlbach, R., & Rodemann, H. P. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-69 · Cited by 202
Hung, L.-Y., Tseng, J. T., Lee, Y.-C., Xia, W., Wang, Y.-N., Wu, M.-L., Chuang, Y.-H., Lai, C.-H., & Chang, W.-C. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn417 · Cited by 196
Butts, C. A., Bodkin, D., Middleman, E. L., Englund, C. W., Ellison, D., Alam, Y., Kreisman, H., Graze, P., Maher, J., Ross, H. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0856 · Cited by 195
Co‐regulation of B‐Myb expression by E2F1 and EGF receptor
Hanada, N., Lo, H., Day, C., Pan, Y., Nakajima, Y., & Hung, M. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20147 · Cited by 188
Role of the Sec61 Translocon in EGF Receptor Trafficking to the Nucleus and Gene Expression
Liao, H.-J., & Carpenter, G. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-09-0802 · Cited by 187
Lo, H.-W., Cao, X., Zhu, H., & Ali-Osman, F. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0391 · Cited by 186
Epidermal Growth Factor Receptor Translocation to the Mitochondria
Demory, M. L., Boerner, J. L., Davidson, R., Faust, W., Miyake, T., Lee, I., Hüttemann, M., Douglas, R., Haddad, G., & Parsons, S. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.000760 · Cited by 184
Grøvdal, L. M., Stang, E., Sorkin, A., & Madshus, I. H. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.07.003 · Cited by 182
Wang, Z., Zhang, L., Yeung, T. K., & Chen, X. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.5.1621 · Cited by 181
Personeni, N., Fieuws, S., Piessevaux, H., De Hertogh, G., De Schutter, J., Biesmans, B., De Roock, W., Capoen, A., Debiec-Rychter, M., Van Laethem, J.-L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0449 · Cited by 174
Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z. H., Mills, G. B., Mendelsohn, J., & Fan, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0589 · Cited by 170
Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma
Perrone, F., Suardi, S., Pastore, E., Casieri, P., Orsenigo, M., Caramuta, S., Dagrada, G., Losa, M., Licitra, L., Bossi, P., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1759 · Cited by 168
Hatakeyama, H., Cheng, H., Wirth, P., Counsell, A., Marcrom, S. R., Wood, C. B., Pohlmann, P. R., Gilbert, J., Murphy, B., Yarbrough, W. G., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012702 · Cited by 162
Self-citationRiedel, H., Dull, T. J., Schlessinger, J., & Ullrich, A. (1986) · Nature · doi:10.1038/324068a0 · Cited by 161
Hendriks, B. S., Opresko, L. K., Wiley, H. S., & Lauffenburger, D. A. (2003) · PubMed · Cited by 159
Wheeler, D. L., Iida, M., Kruser, T. J., Nechrebecki, M. M., Dunn, E. F., Armstrong, E. A., Huang, S., & Harari, P. M. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.8.7903 · Cited by 157
Self-citationTargets of Raf in tumorigenesis
Niault, T., & Baccarini, M. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp337 · Cited by 157
Fischer-Colbrie, J., Witt, A., Heinzl, H., Speiser, P., Czerwenka, K. F., Sevelda, P., & Zeillinger, R. (1997) · PubMed · Cited by 156
Malden, L. T., Novak, U., Kaye, A. H., & Burgess, A. W. (1988) · PubMed · Cited by 156
Bao, J., Gur, G., & Yarden, Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437945100 · Cited by 156
Ohgaki, H., Watanabe, K., Tachibana, O., Sato, K., & Kleihues, P. (1996) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199605000-00017 · Cited by 155
Robert, F., Blumenschein, G., Herbst, R. S., Fossella, F. V., Tseng, J. E., Saleh, M. N., & Needle, M. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1438 · Cited by 154
Xia, W., Wei, Y., Du, Y., Liu, J., Chang, B., Yu, Y., Huo, L., Miller, S. A., & Hung, M. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20504 · Cited by 151
Bianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S., Tarallo, V., De Falco, S., Melisi, D., Benelli, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4905 · Cited by 149
Nielsen, J. S., Jakobsen, E. H., Hølund, B., Bertelsen, K., & Jakobsen, A. K. M. (2004) · International Journal of Gynecological Cancer · doi:10.1111/j.1048-891x.2004.14606.x · Cited by 147
A gene-alteration profile of human lung cancer cell lines
Blanco, R., Iwakawa, R., Tang, M., Kohno, T., Angulo, B., Pío, R., Montuenga, L. M., Minna, J. D., Yokota, J., & Sánchez‐Céspedes, M. (2009) · Human Mutation · doi:10.1002/humu.21028 · Cited by 139
Nuclear targeting of Bax during apoptosis in human colorectal cancer cells
Mandal, M., Adam, L., Mendelsohn, J. M., & Kumar, R. (1998) · Oncogene · doi:10.1038/sj.onc.1202020 · Cited by 137
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
Self-citationMutations of the BRAF gene in squamous cell carcinoma of the head and neck
Weber, A., Langhanki, L., Sommerer, F., Markwarth, A., Wittekind, C., & Tannapfel, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206705 · Cited by 131
Localization of epidermal growth factor receptor in hepatocyte nuclei
Marti, U., Burwen, S. J., Wells, A. H., Barker, M. E., Huling, S. L., Feren, A. M., & Jones, A. L. (1991) · Hepatology · doi:10.1002/hep.1840130104 · Cited by 129
Punt, C. J. A., Tol, J. A. M. G., Rodenburg, C. J., Cats, A., Creemers, G. J. M., Schrama, J. G., Erdkamp, F., Vos, A. H., Mol, L., & Antonini, N. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.lba4011 · Cited by 128
Liu, B., Fang, M., Schmidt, M., Lü, Y., Mendelsohn, J. M., & Fan, Z. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1201 · Cited by 128
O‐charoenrat, P., Rhys‐Evans, P. H., Modjtahedi, H., Court, W. J., Box, G., & Eccles, S. A. (2000) · International Journal of Cancer · Cited by 124
Borner, M., Koeberle, D., Von Moos, R., Saletti, P., Rauch, D., Hess, V., Trojan, A., Helbling, D., Pestalozzi, B., Caspar, C., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn058 · Cited by 124
Responsiveness to Cetuximab without Mutations inEGFR
Tsuchihashi, Z., Khambata‐Ford, S., Hanna, N. H., & Janne, P. A. (2005) · New England Journal of Medicine · doi:10.1056/nejm200507143530218 · Cited by 121
Amplification and overexpression of the egf receptor gene in primary human glioblastomas
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Journal of Cell Science · doi:10.1242/jcs.1985.supplement_3.16 · Cited by 119
Yamabhai, M., & Anderson, R. G. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200277200 · Cited by 116
Cetuximab/C225-Induced Intracellular Trafficking of Epidermal Growth Factor Receptor
Liao, H., & Carpenter, G. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0049 · Cited by 104
Piyathilake, C. J., Frost, A. R., Manne, U., Weiss, H. L., Bell, W. C., Heimburger, D. C., & Grizzle, W. E. (2002) · PubMed · Cited by 103
Weichselbaum, R. R., Dunphy, E. J., Beckett, M. A., Tybor, A. G., Moran, W. J., Goldman, M. E., Vokes, E. E., & Panje, W. R. (1989) · Head & Neck · doi:10.1002/hed.2880110510 · Cited by 89
Chung, B. M., Raja, S. M., Clubb, R. J., Tu, C., George, M., Band, V., & Band, H. (2009) · BMC Cell Biology · doi:10.1186/1471-2121-10-84 · Cited by 89
Sizeland, A. M., & Burgess, A. W. (1992) · Molecular Biology of the Cell · doi:10.1091/mbc.3.11.1235 · Cited by 79
Kim, J., Jahng, W. J., Vizio, D. D., Lee, J. S., Jhaveri, R., Rubin, M. A., Shisheva, A., & Freeman, M. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1333 · Cited by 79
O‐charoenrat, P., Rhys‐Evans, P. H., Court, W. J., Box, G., & Eccles, S. A. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006751016860 · Cited by 76
Epithelial Phenotype Confers Resistance of Ovarian Cancer Cells to Oncolytic Adenoviruses
Strauss, R., Sova, P., Liu, Y., Li, Z. Y., Tuve, S., Pritchard, D. K., Brinkkoetter, P. T., Möller, T. B., Wildner, O., Pesonen, S. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0645 · Cited by 75
Cao, H., Lei, Z. M., Bian, L., & Rao, C. V. (1995) · Endocrinology · doi:10.1210/endo.136.7.7540549 · Cited by 69
Basu, D., Nguyen, T.-T. K., Montone, K. T., Zhang, G., Wang, L.-P., Diehl, J. A., Rustgi, A. K., Lee, J. T., Weinstein, G. S., & Herlyn, M. (2010) · Oncogene · doi:10.1038/onc.2010.170 · Cited by 64
HER2-Mediated Effects on EGFR Endosomal Sorting: Analysis of Biophysical Mechanisms
Hendriks, B. S., Wiley, H. S., & Lauffenburger, D. A. (2003) · Biophysical Journal · doi:10.1016/s0006-3495(03)74696-7 · Cited by 63
Kim, S. M., Kim, J. S., Kim, J.-H., Yun, C., Kim, E. M., Kim, H. K., Solca, F., Choi, S.-Y., & Cho, B. C. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.04.006 · Cited by 61
Specht, B. U., Bartetzko, N., Hohoff, C., Kuhl, H., Franke, R., Börchers, T., & Spener, F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19943 · Cited by 60
Huynh, H. T., Alpert, L., & Pollak, M. (1996) · PubMed · Cited by 56
de Melker, A. A., Horst, G., & Borst, J. G. (2004) · Journal of Cell Science · doi:10.1242/jcs.01354 · Cited by 56
Herbst, R. S., Chansky, K., Kelly, K. L., Atkins, J. N., Davies, A. M., Dakhil, S. R., Albain, K. S., Kim, E. S., Crowley, J. J., & Gandara, D. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7545 · Cited by 53
Nevo, J., Mattila, E., Pellinen, T. S., Yamamoto, D. L., Sara, H., Iljin, K., Kallioniemi, O., Bono, P., Heikkilä, P., Joensuu, H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0773 · Cited by 37
Huang, F., Xu, L., & Khambata‐Ford, S. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-2697 · Cited by 1
(2001) · PubMed
Cited by
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Vyse, S., & Huang, P. H. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0038-9 · Cited by 370
Duffy, M. J., Lamerz, R., Haglund, C., Nicolini, A., Kalousová, M., Holubec, L., & Sturgeon, C. (2014) · International Journal of Cancer · doi:10.1002/ijc.28384 · Cited by 360
Squamous Cell Cancers: A Unified Perspective on Biology and Genetics
Dotto, G. P., & Rustgi, A. K. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.004 · Cited by 319
Soundararajan, R., Fradette, J., Konen, J., Moulder, S., Zhang, X., Gibbons, D., Varadarajan, N., Wistuba, I., Tripathy, D., Bernatchez, C., et al. (2019) · Cancers · doi:10.3390/cancers11050714 · Cited by 103
Metadata
- Authors
- Brand, T. M., Iida, M., & Wheeler, D. L.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2011-05
- Volume
- 11
- Issue
- 9
- Pages
- 777-792
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2093036951
- Cited by
- 273
- References
- 189
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.